Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Gains from Sales and Divestitures: 2015-2025

Historic Gains from Sales and Divestitures for Voyager Therapeutics (VYGR) over the last 9 years, with Sep 2025 value amounting to $568,331.

  • Voyager Therapeutics' Gains from Sales and Divestitures rose 34.24% to $568,331 in Q3 2025 from the same period last year, while for Sep 2025 it was $568,331, marking a year-over-year increase of 34.24%. This contributed to the annual value of $515,303 for FY2024, which is 3.06% down from last year.
  • Voyager Therapeutics' Gains from Sales and Divestitures amounted to $568,331 in Q3 2025, which was up 3.32% from $550,084 recorded in Q2 2025.
  • In the past 5 years, Voyager Therapeutics' Gains from Sales and Divestitures ranged from a high of $568,331 in Q3 2025 and a low of $184,217 during Q1 2021.
  • In the last 3 years, Voyager Therapeutics' Gains from Sales and Divestitures had a median value of $450,556 in 2025 and averaged $456,017.
  • As far as peak fluctuations go, Voyager Therapeutics' Gains from Sales and Divestitures soared by 129.71% in 2021, and later dropped by 13.33% in 2024.
  • Voyager Therapeutics' Gains from Sales and Divestitures (Quarterly) stood at $326,943 in 2021, then spiked by 33.54% to $436,611 in 2022, then rose by 21.75% to $531,560 in 2023, then dropped by 3.06% to $515,303 in 2024, then surged by 34.24% to $568,331 in 2025.
  • Its last three reported values are $568,331 in Q3 2025, $550,084 for Q2 2025, and $450,556 during Q1 2025.